Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative-Reference-Cited by-同舟云学术

Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative

Published:2016 Issue:3 Volume:94 Page:129-137
ISSN:0012-2823
Container-title:Digestion
language:en
Short-container-title:Digestion

Author:

Betge Johannes,Barat Ana,Murphy Verena,Hielscher Thomas,Van Grieken Nicole C.,Belle Sebastian,Zhan Tianzuo,Härtel Nicolai,Kripp Melanie,Bacon Orna,Cordes Martijn,Kay Elaine W.,Verheul Henk M.W.,Neerincx Maarten,Hennessy Bryan,Hofheinz Ralf D.,Gaiser Timo,Ylstra Bauke,Prehn Jochen H.M.,Lambrechts Diether,Byrne Annette T.,Ebert Matthias P.,Schulte Nadine

Publisher

S. Karger AG

Subject

Gastroenterology

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patients;npj Genomic Medicine;2024-05-29

2. A Review of Radiomics in Predicting Therapeutic Response in Colorectal Liver Metastases: From Traditional to Artificial Intelligence Techniques;Healthcare;2022-10-19

3. Predictive value of chromosome 18q11.2‐q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III ‐trial AGITG‐MAX;International Journal of Cancer;2022-05-23

4. Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer;Scientific Reports;2020-06-17

5. Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A;EBioMedicine;2019-07